Polyclonal tumors in the mammalian intestine: Are interactions among multiple initiated clones necessary for tumor initiation, growth, and progression?

Cell Cycle

Volumn 6, Issue 1, 2007, Pages 44-51

  Halberg, Richard B ^a   Dove, William F ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

And EgfR; Apc; Cox 2; Crypt purification; Intestinal cancer; Polyclonal structure; Random collision; Short range interactions

Indexed keywords

CARCINOGENESIS; CELL INTERACTION; CELL TRANSFORMATION; CLONAL VARIATION; COLORECTAL TUMOR; HUMAN; INTESTINE TUMOR; MOSAICISM; NONHUMAN; REGULATORY MECHANISM; REVIEW; TUMOR GROWTH;

MAMMALIA;

EID: 33846614926     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.1.3651     Document Type: Review

References (65)

1. American Cancer Society. Colorectal Cancer Facts and Figures Special Edition 2005.
2. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87:159-70.
3. Novelli MR, Williamson JA, Tomlinson IPM, Elia G, Hodgson SV, Talbot IC, Bodmer WF, Wright NA. Polyclonal origin of colonic adenomas in an XO/XY patient with FAP. Science 1996; 272:1187-90.
4. + from all tumor lineages. Proc Natl Acad Sci USA 1997; 94:13927-31.
5. Winton DJ, Ponder BAJ. Stem-cell organization in mouse small intestine. Proc R Soc Lond B Biol Sci 1990; 241:13-8.
6. Schmidt GH, Winton DJ, Ponder BAJ. Development of the pattern of cell renewal in the crypt-villus unit of chimaeric mouse small intestine. Development 1988; 103:785-90.
7. Cairns J. Mutation selection and the natural history of cancer. Nature 1975; 255:197-200.
8. Shibata D, Schaeffer J, Li ZH, Capella G, Perucho M. Genetic heterogeneity of the c-K-ras locus in colorectal adenomas but not in adenocarcinomas. J Natl Cancer Inst 1993; 85:1058-63.
9. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, Hamilton S, Vogelstein B. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990; 50:7717-22.
10. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319:525-32.
11. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D, Kruhoffer M, Aaltonen L, Orntoft TF, Quackenbush J, Yeatman TJ. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005; 23:3526-35.
12. Kwong KY, Bloom GC, Yang I, Boulware D, Coppola D, Haseman J, Chen E, McGrath A, Makusky AJ, Taylor J, Steiner S, Zhou J, Yeatman TJ, Quackenbush J. Synchronous global assessment of gene and protein expression in colorectal cancer progression. Genomics 2005; 86:142-58.
13. Bulow S. Familial polyposis coli. Dan Med Bull 1987; 34:1-15.
14. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M, Sargeant L, Krapcho K, Wolff E, Burt R, Hughes JP, Warrington J, McPherson J, Wasmuth J, Le Paslier D, Adberrahim H, Cohen D, Leppert M, White R. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991; 66:589-600.
15. Haggitt RC, Reid BJ. Hereditary gastrointestinal polyposis syndromes. Am J Surg Pathol 1986; 10:871-87.
16. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta 1997; 1332:F127-F148.
17. Ben Ze'ev A, Geiger B. Differential molecular interactions of β-catenin and plakoglobin in adhesion, signaling and cancer. Curr Opin Cell Biol 1998; 10:629-39.
18. Morrison EE, Wardleworth BN, Askham JM, Markham AF, Meredith DM. EB1, a protein which interacts with the APC tumour suppressor, is associated with the microtubule cytoskeleton throughout the cell cycle. Oncogene 1998; 17:3471-7.
19. Fearon ER, Hamilton SR, Vogelstein B. Clonal analysis of human colorectal tumors. Science 1987; 238:193-7.
20. Beutler E, Collins Z, Irwin LE. Value of genetic variants of glucose-6-phosphate dehydrogenase in tracing the origin of malignant tumors. N Engl J Med 1967; 276:389-91.
21. Hsu SH, Luk GD, Krush AJ, Hamilton SR, Hoover HH. Multiclonal origin of polyps in Gardner syndrome. Science 1983; 221:951-3.
22. Novelli M, Cossu A, Oukrif D, Quaglia A, Lakhani S, Poulsom R, Sasieni P, Carta P, Contini M, Pasca A, Palmieri G, Bodmer W, Tanda F, Wright N. X-inactivation patch size in human female tissue confounds the assessment of tumor clonality. Proc Natl Acad Sci USA 2003; 100:3311-4.
23. Griffiths DFR, Williams D, Williams GT, Williams ED. The clonal origin of experimental large bowel tumours. Br J Cancer 1989; 59:385-7.
24. Thliveris AT, Halberg RB, Clipson L, Dove WF, Sullivan R, Washington MK, Stanhope S, Newton MA. Polyclonality of familial murine adenomas: Analyses of mouse chimeras with low tumor multiplicity suggest short-range interactions. Proc Natl Acad Sci USA 2005; 102:6960-5.
25. Newton MA, Clipson L, Thliveris AT, Halberg RB. A statistical test of the hypothesis that polyclonal intestinal tumors arise by the random collision of initiated clones. Biometrics 2006; 62:721-7.
26. Newton MA. On estimating the polyclonal fraction in lineage-marker studies of tumor origin. Biostatistics 2006; 7:503-14.
27. Kim KM, Shibata D. Tracing ancestry with methylation patterns: Most crypts appear distantly related in normal adult human colon. BMC Gastroenterol 2004; 4:8.
28. Greaves LC, Preston SL, Tadrous PJ, Taylor RW, Barron MJ, Oukrif D, Leedham SJ, Deheragoda M, Sasieni P, Novelli MR, Jankowski JA, Turnbull DM, Wright NA, McDonald SA. Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission. Proc Natl Acad Sci USA 2006; 103:714-9.
29. Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 2005; 436:272-6.
30. Gardner RL. Extrinsic factors in cellular differentiation. Int J Dev Biol 1993; 37:47-50.
31. Gurdon JB, Lemaire P, Kato K. Community effects and related phenomena in development. Cell 1993; 75:831-4.
32. Gehring WJ. Homeo boxes in the study of development. Science 1987; 236:1245-52.
33. Rous P, Kidd JG. Conditional neoplasms and subthreshold neoplastic states. J Exp Med 1940; 73:365-95.
34. 2/M cell cycle block in transformed cells by contact with normal neighbors. Cell Cycle 2003; 2:484-7.
35. Hill R, Song Y, Cardiff RD, Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2005; 123:1001-11.
36. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997; 386:761-763.
37. Clarke AR. Studying the consequences of immediate loss of gene function in the intestine: APC. Biochem Soc Trans 2005; 33:665-6.
38. 1638N mice reveal a mutational signature of Mlh1 deficiency. Oncogene 2000; 19:5755-63.
39. 1638N mice define the roles of MSH3 and MSH6 in DNA repair and intestinal tumorigenesis. Cancer Res 2001; 61:7934-42.
40. Bjerknes M, Cheng H. Colossal crypts bordering colon adenomas in Apc(Min) mice express full-length Apc. Am J Pathol 1999; 154:1831-4.
41. Haigis KM, Dove WF. A Robertsonian translocation suppresses a somatic recombination pathway to loss of heterozygosity. Nat Genet 2003; 33:33-9.
42. Meniel V, Hay T, Douglas-Jones A, Sansom OJ, Clarke AR. Mutations in Apc and p53 synergize to promote mammary neoplasia. Cancer Res 2005; 65:410-6.
43. Halberg RB, Katzung DS, Hoff PD, Moser AR, Cole CE, Lubet RA, Donehower LA, Jacoby RF, Dove WF. Tumorigenesis in the multiple intestinal neoplasia mouse: Redundancy of negative regulators and specificity of modifiers. Proc Natl Acad Sci USA 2000; 97:3461-6.
44. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23:254-66.
45. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: Rationale and promise. Cancer Cell 2003; 4:431-6.
46. 716 knockout mice by inhibition of cyclooxygenase (COX-2). Cell 1996; 87:803-9.
47. Min/+ mouse model of intestinal tumorigenesis. Carcinogenesis 2006; 27:382-91.
48. Buchanan FG, Wing D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003; 278:35451-7.
49. Shao J, Lee SB, Guo H, Evers BM, Sheng H. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 2003; 63:5218-23.
50. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002; 8:289-93.
51. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L, Kronenberg M, Miller PW, Portanova J, Lee JC, Dubinett SM. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000; 164:361-70.
52. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H, Dubinett SM. Nonsmall cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: Up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998; 58:1208-16.
53. Balch CM, Dougherty PA, Cloud GA, Tilden AB. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery 1984; 95:71-7.
54. Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol 1983; 3:295-315.
55. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83:493-501.
56. Cohen EG, Almahmeed T, Du B, Golijanin D, Boyle JO, Soslow RA, Subbaramaiah K, Dannenberg AJ. Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma. Clin Cancer Res 2003; 9:3425-30.
57. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58:362-6.
58. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001; 276:18075-81.
59. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani CM. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000; 6:1024-8.
60. Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer 1954; 8:1-12.
61. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6:963-8.
62. Reddy AL, Fialkow PJ. Papillomas induced by initiation-promotion differ from those induced by carcinogen alone. Nature 1983; 304:69-71.
63. Wernert N, Locherbach C, Wellmann A, Behrens P, Hugel A. Presence of genetic alterations in microdissected stroma of human colon and breast cancers. Anticancer Research 2001; 21:2259-64.
64. Nexo E, Kryger-Baggesen N. The receptor for epidermal growth factor is present in human fetal kidney, liver and lung. Regul Pept 1989; 26:1-8.
65. Venook AP. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer 2005; 103:2435-46.